TransMedics Group Inc. Stock News

ANDOVER, Mass. , June 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-

Medical devices are spearheading the digitalization of healthcare, reports analytics and software development company Luxoft. Specifically, medical devices are “providing accurate diagnoses, effecti

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a

ANDOVER, Mass. , May 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe

TransMedics blew past Wall Street's expectations with its Q1 earnings report. Demand for the company's Organ Care System remains incredibly robust.

TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President &

TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago.

ANDOVER, Mass. , April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end

Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during th